withdrawal studies may employ more personalized, science-based decision making, stratifying patients according to validated assessments for their propensity for tolerance. As well, these findings provide a basis for new studies in both humans and animal models to better understand solid organ transplant tolerance and the important and unique contributions that the liver, an immune organ itself, makes to the tolerance process following liver transplantation.
demonstrates that antibodies reduce the efficacy of this therapeutic approach for the LSD mucopolysaccharidosis I (MPS I) and identifies an immunosuppressive regimen that is highly effective at blocking antibody formation when given at the time of initiation of protein therapy in dogs with MPS I.
Enzyme replacement therapy for LSDs
LSDs are due to a deficiency in any of several enzymes that degrade various sub-strates. Although most of the enzyme in a normal cell derives from de novo synthesis and translocation to the lysosome, enzyme can also be taken up from outside the cell. This process has served as the basis for a treatment called enzyme replacement therapy (ERT), in which enzyme is injected i.v., diffuses to cells in many parts of the body, and is taken up via a receptor and translocated to the lysosome. The first LSD that was treated with ERT was Gaucher disease, which is due to deficiency of the lysosomal acid β-glucosidase. It was demonstrated in the early 1990s that purified enzyme that was modified with mannose residues could be taken up by macrophages via the mannose receptor and reduce the clinical manifestations in patients with the nonneuropathic form of Gaucher disease (3). Although antibodies developed in approximately 15% of patients, they did not usually affect the efficacy of treatment (4). This may reflect the fact that macrophages are the target cell, and macrophages contain IgG receptors that could take up the enzyme present in immune complexes. ERT has been developed more recently for several other LSDs, including MPS I, MPS II, MPS VI, Fabry disease, and Pompe disease (5) . For all of these diseases, enzyme must be taken up by cells other than macrophages for an appropriate therapeutic effect to be achieved, as summarized in Table 1 . For this reason, the enzymes used for all of these disorders have been modified with mannose 6-phosphate (M6P), as the M6P receptor is present on most cells. Antibodies have developed in several studies, but their effect on ERT has been somewhat unclear.
Anti-IDUA antibodies develop after ERT for MPS I
MPS I is due to deficiency in α-l-iduronidase (IDUA) and results in the accumulation of the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate. In the initial study of ERT with IDUA for MPS I, only 40% of patients developed anti-IDUA antibodies, and these did not appear to alter the clinical effect (6) . However, none of these initial patients had IDUA-null mutations. In a more recent study in which 70% of the patients had IDUA-null mutations, all patients developed anti-IDUA antibodies, and those with anti-IDUA antibody titers that were greater than 1:10,000 had relatively modest reductions in urine GAG levels when compared with the reduction in patients with low or undetectable titers of anti-IDUA antibodies (7) . Although these results suggest that anti-IDUA antibodies reduce the efficacy of ERT for MPS I, the critical test is whether enzyme is delivered to tissues and can reduce the biochemical, pathological, and clinical manifestations of disease. It is difficult to assess this response in patients, as biopsies of organs or tissues cannot readily be performed.
Anti-IDUA antibodies reduce the efficacy of ERT for MPS I
The current study by Dickson et al. (2) evaluates the effect of anti-IDUA antibody formation on disease manifestations in MPS I dogs that received ERT with recombinant human IDUA. This group had previously demonstrated that MPS I dogs that received i.v. injection of M6P-modified recombinant human IDUA consistently developed anti-IDUA antibodies (8, 9) , but the significance of this antibody production was unclear. In their current article (2), the authors compare the effect of ERT on disease manifestations in MPS I dogs with high titers of anti-IDUA antibodies with that seen in MPS I dogs that were tolerized to recombinant human IDUA using the regimen detailed below. They demonstrate that high titers of anti-IDUA antibodies reduced the uptake of IDUA by MPS I fibroblasts to less than 10% of that seen with serum from animals with low or negative titers of antibodies. Furthermore, anti-IDUA antibodies reduced delivery of enzyme to organs with low levels of macrophages and reduced the ability of ERT to lower GAG levels. For example, IDUA enzyme activity was 2.4- and 5.1-fold higher, respectively, in heart valves and the renal medulla in tolerant dogs than in dogs with high-titer antibodies after administration of the standard dose of 0.58 mg/kg/wk of recombinant human IDUA, while the pathological abnormalities in heart valves and renal medulla, respectively, were only 24% and 60% as severe in tolerized dogs compared with dogs with high-titer antibodies. Furthermore, although a 3.4-foldhigher dose of 2 mg/kg/wk further reduced pathological evidence of lysosomal storage in tolerized MPS I dogs, this higher dose was not as effective in animals with hightiter antibodies. These data provide compelling evidence that anti-IDUA antibodies adversely affect the efficacy of ERT. The anti-IDUA antibody probably binds to an epitope at or near the M6P modification and sterically inhibits the protein from binding to the M6P receptor and being taken up by the cell, as diagrammed in Figure 1 . This study also suggests that the dose of enzyme that is currently used for ERT is too low to be effective at some sites. Early studies to identify the appropriate dose relied upon reduction in lysosomal storage in easy-to-treat organs such as liver and spleen (6) , and these doses may need to be revised based on these data.
Immunosuppressive regimen used to induce tolerance
The immunosuppressive regimen used to tolerize MPS I dogs was remarkable for its (20) high success rate, as 100% of 14 MPS I dogs that were treated in this (2) and a previous (10) study were successfully tolerized. Although the initial dose of cyclosporine A (25 mg/kg) was approximately 3-fold greater than the average dose used for organ transplantation and the initial target cyclosporine trough level in blood was relatively high, at 400 ng/ml, the dose was reduced to 12.5 mg/kg after 1 month, 6.25 mg/mg after 1.5 months, and was discontinued after 2 months. The starting dose of azathioprine (5 mg/kg) every other day was approximately 50% of the dose used for renal transplantation and was similarly reduced to 50% and 25% of the initial dose after 1 and 1.5 months, respectively, and then discontinued after 2 months. Thus, the immunosuppressive regimen was relatively mild, and indeed, no serious adverse effects were reported in any animals. Although this approach appeared to be extraordinarily effective in MPS I dogs, the choice of cyclosporine A was a bit surprising, as some studies have demonstrated that cyclosporine A blocks activation-induced cell death of effector T cells and is detrimental to tolerance induction by costimulation blockade (11) (12) (13) (14) . Azathioprine appears to be a more logical choice, as it has been reported to block CD28-dependent costimulatory signaling (15) . Indeed, although administration of cyclosporine A with azathioprine induced tolerance in 1 of 1 dogs that received the enzyme deficient in Pompe disease (acid α-glucosidase), an identical regimen was not effective in mice with Pompe disease (16) . In addition, this regimen was not effective at inducing tolerance to soluble proteins that did not contain M6P, such as ovalbumin or IDUA that had been enzymatically treated to remove the M6P. Further investigation will clearly be required to identify the mechanism by which this particular regimen induced tolerance to M6P-modified IDUA, to test its efficacy for inducing tolerance to other proteins, and to determine whether it can prevent antibody formation in humans.
In conclusion, the current study by Dickson et al. (2) demonstrates that antibodies against recombinant human IDUA can reduce the efficacy of ERT for MPS I in dogs. Importantly, the study identifies a highly effective and transient immunosuppressive regimen that can prevent antibody formation in 100% of dogs without any overt adverse effects. It is likely that this or other immunosuppressive protocols will become routine at the initiation of ERT for LSD or of protein therapy for other genetic diseases, as patients with null mutations will likely be at high risk for antibody formation. Thus, for these disorders, a stitch in time saves nine in our efforts to provide an effective treatment for these patients. In some MPS I patients, a significant immune response to ERT has been shown; however, little was known about the effect of anti-enzyme antibodies on treatment outcome. In this issue of the JCI, Dickson et al. (2) show that in dogs with MPS I receiving IDUA via ERT, anti-IDUA antibodies may develop and bind to IDUA and sterically block MP6 from binding M6PR. This results in a failure of the enzyme to reach the lysosome and lack of a therapeutic effect. The authors go on to demonstrate that the induction of IDUA-specific immune tolerance in these animals, compared with dogs that were not tolerized to IDUA, improved IDUA uptake, increased GAG degradation, and reduced tissue pathology. Therefore, transient immunosuppression may enhance ERT for LSDs.
